Literature DB >> 15849048

Successful treatment of Staphylococcus epidermidis prosthetic valve endocarditis with linezolid after failure of treatment with oxacillin, gentamicin, rifampicin, vancomycin, and fusidic acid regimens.

P W de Feiter1, J A Jacobs, M J H M Jacobs, C Vink, S van der Geest.   

Abstract

We present a 49-y-old male, with a history of Marfan's disease and aortic and mitral valve replacement surgery, who was operated for a type III thoracoabdominal aneurysm. The postoperative course was compromised by a Staphylococcus epidermidis mitral valve endocarditis, which was successfully treated only after intravenous linezolid was included in the therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15849048     DOI: 10.1080/00365540410021018

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  4 in total

Review 1.  Infective endocarditis treated with linezolid: case report and literature review.

Authors:  E E Hill; P Herijgers; M-C Herregods; W E Peetermans
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-03       Impact factor: 3.267

2.  The role of polysaccharide intercellular adhesin (PIA) in Staphylococcus epidermidis adhesion to host tissues and subsequent antibiotic tolerance.

Authors:  A R Costa; M Henriques; R Oliveira; J Azeredo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-01-08       Impact factor: 3.267

Review 3.  Endocarditis in Patients with Aortic Valve Prosthesis: Comparison between Surgical and Transcatheter Prosthesis.

Authors:  Micaela De Palo; Pietro Scicchitano; Pietro Giorgio Malvindi; Domenico Paparella
Journal:  Antibiotics (Basel)       Date:  2021-01-06

4.  Linezolid for infective endocarditis: A structured approach based on a national database experience.

Authors:  P Muñoz; S De la Villa; M Martínez-Sellés; M A Goenaga; K Reviejo-Jaka; F Arnáiz de Las Revillas; L García-Cuello; C Hidalgo-Tenorio; M A Rodríguez-Esteban; I Antorrena; L Castelo-Corral; E García-Vázquez; J De la Torre; E Bouza
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.